Investigating in vitro and in vivo αvβ6 integrin receptor-targeting liposomal alendronate for combinatory γδ T cell immunotherapy.

J Control Release · 2017 · PMC5488751 · PMID 28432037

Europe PMC DOI

hedged sentence

0.1500

closest p · 3.0× alpha

0.1500

boldest claim

The sentences

showed a trendp = 0.15not close (p > 0.1)

Monotherapy with t-L-ALD showed a trend towards greater effectiveness than L-ALD (4.70 × 10 8 ± 1.78 × 10 8 vs. 1.24 × 10 9 ± 4.65 × 10 8 photons, day 27, p = 0.15).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.